Research map: Liquid biopsy in breast cancer: current biomarker platforms and clinical applications

Back to the article

Papers in this map

  1. Comprehensive molecular portraits of human breast tumours · The Cancer Genome Atlas Network · 2012 · 12644 citations · Cited by this paper
  2. Emerging roles of haemostatic proteins as markers of disease progression and prognosis in breast cancer · 2026 · Related
  3. Current and future burden of breast cancer: Global statistics for 2020 and 2040 · Melina Arnold · 2022 · 3421 citations · Cited by this paper
  4. FDA 2025 Cancer Drug Approvals: targeted therapy dominates · 2026 · Related
  5. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer · Sarah‐Jane Dawson · 2013 · 2250 citations · Cited by this paper
  6. Racial disparities in hepatocellular carcinoma: a TCGA-based gene expression study of Caucasian and Asian populations · 2025 · Related
  7. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA · M.C. Liu · 2020 · 1574 citations · Cited by this paper
  8. Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer · 2025 · Related
  9. Genome-wide cell-free DNA fragmentation in patients with cancer · Stephen Cristiano · 2019 · 1563 citations · Cited by this paper
  10. Benign, persistent, and invasive: mechanistic and translational approaches to middle‑ear cholesteatoma · 2026 · Related
  11. Enhanced detection of circulating tumor DNA by fragment size analysis · Florent C. Mouliere · 2018 · 1139 citations · Cited by this paper
  12. Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia · 2026 · Related
  13. Liquid Biopsy: From Discovery to Clinical Application · Catherine Alix-Panabières · 2021 · 1004 citations · Cited by this paper
  14. Reactive oxygen species (ROS) in cancer: from redox signaling and metabolic plasticity to therapeutic vulnerabilities · 2026 · Related
  15. Liquid biopsy in cancer: current status, challenges and future prospects · Liwei Ma · 2024 · 686 citations · Cited by this paper
  16. Socioeconomic impact of artificial intelligence–driven point-of-care testing devices for liquid biopsy in the OncoCheck system · 2025 · Related
  17. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer · Gaia Schiavon · 2015 · 583 citations · Cited by this paper
  18. Point-of-Care testing: an ally for precision oncology · 2025 · Related
  19. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer · Jamie O. Brett · 2021 · 439 citations · Cited by this paper
  20. A novel point-of-care device for monitoring circulating miRNA-107 in prostate cancer: towards a user-friendly liquid biopsy · 2025 · Related
  21. Current Strategies for Exosome Cargo Loading and Targeting Delivery · Haifeng Zeng · 2023 · 424 citations · Cited by this paper
  22. Liquid biopsies: the future of cancer early detection · Siobhan Connal · 2023 · 377 citations · Cited by this paper
  23. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility · Michail Ignatiadis · 2015 · 360 citations · Cited by this paper
  24. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial · François‐Clément Bidard · 2022 · 350 citations · Cited by this paper
  25. Overview of breast cancer · Elyse J. Watkins · 2019 · 274 citations · Cited by this paper
  26. Circulating tumor DNA as an early cancer detection tool · Andrea Campos-Carrillo · 2019 · 259 citations · Cited by this paper
  27. MicroRNAs - Biology and clinical applications · Kannan Ranganathan · 2014 · 223 citations · Cited by this paper
  28. Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer · Francesca Riva · 2017 · 220 citations · Cited by this paper
  29. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial · Ines Stevic · 2018 · 213 citations · Cited by this paper
  30. Clinical application and detection techniques of liquid biopsy in gastric cancer · Shuo Ma · 2023 · 194 citations · Cited by this paper
  31. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy · Mark Jesus M. Magbanua · 2023 · 194 citations · Cited by this paper
  32. Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer · François‐Clément Bidard · 2020 · 185 citations · Cited by this paper
  33. First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer · François‐Clément Bidard · 2025 · 167 citations · Cited by this paper
  34. The Secret Life of Exosomes · Eduardo Marbán · 2018 · 161 citations · Cited by this paper
  35. CA 15–3: A Prognostic Marker in Breast Cancer · Michael Joe Duffy · 2000 · 144 citations · Cited by this paper
  36. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial · Françoise Rothé · 2019 · 130 citations · Cited by this paper
  37. A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer · Ji-Guang Han · 2017 · 126 citations · Cited by this paper
  38. Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy · Pauline Gilson · 2022 · 125 citations · Cited by this paper
  39. Acquired resistance in cancer: towards targeted therapeutic strategies · Alice Soragni · 2025 · 119 citations · Cited by this paper

Source: OpenAlex (CC0)